Showing promise in the landscape of weight management therapy, retatrutide is a different approach. Unlike many existing medications, retatrutide works as a twin agonist, concurrently affecting both GLP-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. The concurrent engagement encourages various advantageous